NEW YORK, Aug. 13 (GenomeWeb News) - Lynx Therapeutics reported that it has signed a non-binding letter of intent to merge with the privately held, UK-based company Solexa. Solexa will provide Lynx with up to $2.5 million in loans to sustain Lynx's operations.
Registering provides access to this and other free content.
Already have an account?Login Now.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.